Vertex drug helps hepatitis C patients Oct 29, 2009
Vertex Pharmaceuticals Inc. said Wednesday its hepatitis C treatment telaprevir created an immune system response to the virus in patients who had not been helped by other drugs. The results came from a midstage trial of the experimental drug. (Yahoo News -- Pharmaceutical Industry News)
Most economic summit organizers are Patrick donors Oct 29, 2009
Boger is the founder of Vertex Pharmaceuticals and serves on its board after stepping down this year as CEO.. The Patrick administration for weeks has promoted an economic summit as one of its answers to the steady loss of jobs in Massachusetts, a key planning and positioning session for Massachusetts. (Arlington Advocate, MA)
Vertex Pharmaceuticals up after loss Oct 28, 2009
(Vertex Pharmaceuticals). October 28, 2009. (Boston Globe)
Vertex loss grows on increased development costs Oct 28, 2009
Vertex Pharmaceuticals Inc. reported a larger third-quarter loss on Monday, as revenue fell and the company spent more money to support the launch of its hepatitis C drug candidate. Vertex posted a loss of $149. (Yahoo News -- Pharmaceutical Industry News)
Insider Report: Selling topped $18M in Aug. Insider Report: Selling totaled $53M in July Oct 27, 2009
Boger, Joshua S. VERTEX PHARMACEUTICALS INC. VRTX $1,098,624 ... Graves, Kurt C. VERTEX PHARMACEUTICALS INC. VRTX $129,462 ... Mueller, Peter VERTEX PHARMACEUTICALS INC. VRTX $78,912. (Boston Business Journal, MA)
The Dollar Kerfuffle Oct 9, 2009
It's top five holdings include Amgen, Gilead Sciences, Celgene, Vertex Pharmaceuticals and Alexion Pharmaceuticals. Its expense ratio is 0. (Human Events Online)
Tewksbury woman receives alumni award Sep 26, 2009
The College of Liberal Arts and Sciences at Northern Illinois University recently announced the 50 recipients of its Golden Anniversary Alumni Award, including Susan Tomlinson of Tewksbury, a scientific software developer at Vertex Pharmaceuticals in Tewksbury ... Roberts shifted her career focus to scientific software development after moving on to Vertex Pharmaceuticals in 2008. (Tewksbury Advocate, MA)
Gene Predicts Response to Hepatitis C Drugs Aug 18, 2009
The drugs are now in mid-stage development by Schering-Plough and Vertex Pharmaceuticals Inc.. Reuters Health. (MEDLINEplus)
Healthy Returns for Pharmaceutical Funds Jul 18, 2009
He's a big holder of Vertex Pharmaceuticals (NasdaqGS: - ), which is in the late stages of testing a drug for Hepatitis C. "The benefit over the current standard of care would be substantial -- and would make Vertex attractive," says Jenner, who has managed the fund since 2000 ... Vertex Pharmaceuticals. (Yahoo News -- Pharmaceutical Industry News)
Insider report: Raytheon's Swanson chooses cash option Jul 16, 2009
Boger, Kenneth S VERTEX PHARMACEUTICALS INC VRTX $3,888,036 ... Cordes, Eugene H VERTEX PHARMACEUTICALS INC VRTX $136,768. (Boston Business Journal, MA)
Children's in cystic fibrosis trial test Jun 26, 2009
The Cystic Fibrosis Center at the hospital is the first site to begin recruiting patients for the 48-week international clinical trial to test the VX-770 drug developed by Vertex Pharmaceuticals Inc. of Cambridge, Mass. Cystic fibrosis is a genetic disease that affects approximately 30,000 people in the U.S. and 70,000 people worldwide. (Buffalo Business First, NY)
Families of Spinal Muscular Atrophy Announces Latest Developments on Three SMA Drug Discovery Programs Jun 19, 2009
This is the program previously worked on by Vertex Pharmaceuticals and deCODE genetics, and fully funded by Families of SMA.. The next step for this program is to request a pre-IND meeting with the FDA and to prepare the required data package. (PR Newswire)
Do You Have the Guts to Buy? Jun 17, 2009
Then again, Vertex Pharmaceuticals (Nasdaq: VRTX) is up 188% since David's teamtold us about it, while the team closed out its Myriad Genetics (Nasdaq: MYGN) position for a 250% gain. That's pretty decent. (MSNBC -- Business)
Insider report: Bruker cashes out Laukien family in millions Jun 6, 2009
Smith, Ian F $965,557 VERTEX PHARMACEUTICALS INC VRTX ... Mueller, Peter $438,860 VERTEX PHARMACEUTICALS INC VRTX ... Sanders, Charles Addison $296,434 VERTEX PHARMACEUTICALS INC VRTX. (Boston Business Journal, MA)
ChemGenex Says Drug Rids Leukemia From Blood in 85% of Patients in Trials Jun 2, 2009
Merck & Co. stopped recruiting patients for trials of a similar product developed with Vertex Pharmaceuticals Inc. in 2007 because of adverse reactions. Gleevec, also sold as Glivec, earned Basel, Switzerland- based Novartis last year, according to Bloomberg data. (Bloomberg -- Australia & New Zealand)
Senate hits backat Patrick on ethics May 13, 2009
The Seventy-First Fund has collected contributions from prominent executives and entrepreneurs, including Cleve Killingsworth, chief executive of Blue Cross/Blue Shield; former Citizens Financial Group chairman Lawrence Fish; and Joshua Boger, chief executive of Vertex Pharmaceuticals. Patriots owner Robert Kraft donated $5,500 to the fund in December, just after the administration designated 500 acres near Foxboro Stadium as a growth district, making it eligible for fast-track approvals and... (Boston Globe)
Hepatitis C: Added Anti-viral Improves Response, Halves Duration Of Treatment, Study Suggests May 7, 2009
The study was funded by Vertex Pharmaceuticals, the maker of the drug telaprevir, a protease inhibitor that works by blocking an enzyme that the hepatitis C virus needs in order to replicate itself ... Other researchers involved in this study include Gregory Everson of the University of Colorado Health Science Center; Stuart Gordon of Henry Ford Hospital; Ira Jacobson of Weill Cornell Medical College; Mark Sulkowski of Johns Hopkins School of Medicine; and Robert Kauffman, Lindsay McNair and... (Science Daily)
Studies: Drug Shows Promise Against Hepatitis C May 2, 2009
The findings also suggest the drug telaprevir, made by Vertex Pharmaceuticals Inc., which sponsored the two studies, can cut treatment time from one year to six months. However, those taking the drug reported more side effects including severe rash, nausea and anemia than those on standard treatment alone. (Newsmax)
Telaprevir with Peginterferon and Ribavirin for Chronic HCV Infection Apr 30, 2009
From the Duke Clinical Research Institute and Duke University, Durham, NC (J.G.M., A.J.M.); the Division of Gastroenterology and Hepatology, University of Colorado Health Science Center, Denver (G.T.E.); Division of Hepatology, Henry Ford Hospital, Detroit (S.C.G.); Division of Gastroenterology and Hepatology, Weill Cornell Medical College, New York (I.M.J.); Johns Hopkins University, Baltimore (M.S.); and Vertex Pharmaceuticals, Cambridge, MA (R.K., L.M., J.A.). Address reprint requests to Dr.... (New England Journal of Medicine)
Danvers firm wins recognition Apr 28, 2009
A top-ranked construction management firm by such leading publications as ENR and Building Design & Construction, Berry has an impressive portfolio of institutional and corporate clients throughout New England, including Brigham and Women s Hospital, Dartmouth College, Harvard Medical School, Massachusetts Institute of Technology, and Vertex Pharmaceuticals, among others. For more information about William A. Berry & Son, Inc., visit the company s web site at www. (Danvers Herald, MA)
Insider report: Selling topped $176M in the first quarter Apr 11, 2009
Brandt, Eric - VERTEX PHARMACEUTICALS INC. - $907,500 ... Mueller, Peter - VERTEX PHARMACEUTICALS INC. - $255,896 ... Lewis-Hall, Freda - VERTEX PHARMACEUTICALS INC. - $36,388. (Boston Business Journal, MA)
BioMed Realty Trust Receives LEED(R) Gold Certification at Center for Life Science | Boston Apr 3, 2009
In addition, BioMed is in the process of obtaining LEED(R) certification for its 675 West Kendall Street building in Cambridge, Massachusetts which is 100% leased to Vertex Pharmaceuticals, and is targeting Gold LEED(R) certification. Kent Griffin, BioMed's President and Chief Financial Officer, remarked, "With Gold certification for the Center for Life Science | Boston, we now have more than 1.2 million square feet of LEED(R)-certified laboratory and office space in the Cambridge/Boston market.... (PR Newswire)
Battle Signs: Merck And J&J? Mar 11, 2009
The Merck-Schering-Plough merger could also impact Vertex Pharmaceuticals (nasdaq: - - ), which is developing a new drug with Johnson on to treat hepatitis C, according to Brian Abrahams, a biotechnology analyst at Oppenheimer /p. Vertex has been racing Schering to bring a new hepatitis C treatment to market. (Forbes -- Business)
Boger to deliver Five Ventures keynote Mar 7, 2009
Vertex Pharmaceuticals (NASDAQ:VRTX) is a Massachusetts-based-based biotechnology company. The Five Ventures competition tests the business acumen of startup companies for a chance to win more than $100,000 in cash and in-kind services. (Charlotte Business Journal, NC)
